Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) soared as it reported success for its Hepatitis C drug. The company said that its ACH-3102, when used in combination with Gilead Sciences, Inc. (NASDAQ:GILD)’s Sovaldi (sofosbuvir) (400 mg) achieved 12 weeks of sustained viral response (SVR) in patients. The clinical trial was conducted on a small group of patients, with a high baseline viral load, for a period of six weeks. The patients remained free of virus for 12 weeks after stopping the dose.
100% Sustained Viral Response (SVR)
The six weeks treatment is half the duration of what patients need to go through under other hepatitis C drugs. The 12 patients, however, did not include those with type 1 hepatitis C, a common, but hardest to cure form of hepatitis. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) drug targets on hot area for hepatitis C, but does not include ribavirin or interferon, standard regimens included in all hepatitis C drugs that accompany high side effects.
Reduced Treatment Duration
CMO, Dr. David Apelian said that the 100% SVR12 achievement following six weeks of the treatment in patients with high baseline viral load is extremely positive for the company. The high baseline viral load patients often require extended duration of medication, but their response in six weeks reaffirms the faith that ACH-3102 could drastically cut the treatment time. He added that the company is preparing to initiate SPARTA Phase 2 program in order to evaluate short treatment durations with the company’s ACH-3102 and ACH-3422 combined with or without Sofosbuvir.
As the company furnished positive details from its study, its shares too showed the investors optimism. The stock ended the last session 7.76% up at $11.66. The shares of the company have grown three times over the last one year as the bio pharma company keeps building the confidence in its investors.